Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer

Swinson, D. E. B., Cox, G., & O'Byrne, Kenneth J. (2004) Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. BJC : British Journal of Cancer, 91(7), pp. 1301-1307.

View at publisher


The epidermal growth factor receptor (EGFR) is commonly expressed in non-small-cell lung cancer (NSCLC) and promotes a host of mechanisms involved in tumorigenesis. However, EGFR expression does not reliably predict prognosis or response to EGFR-targeted therapies. The data from two previous studies of a series of 181 consecutive surgically resected stage I-IIIA NSCLC patients who had survived in excess of 60 days were explored. Of these patients, tissue was available for evaluation of EGFR in 179 patients, carbonic anhydrase (CA) IX in 177 patients and matrix metalloproteinase-9 (MMP-9) in 169 patients. We have previously reported an association between EGFR expression and MMP-9 expression. We have also reported that MMP-9 (P=0.001) and perinuclear (p)CA IX (P=0.03) but not EGFR expression were associated with a poor prognosis. Perinuclear CA IX expression was also associated with EGFR expression (P<0.001). Multivariate analysis demonstrated that coexpression of MMP-9 with EGFR conferred a worse prognosis than the expression of MMP-9 alone (P<0.001) and coexpression of EGFR and pCA IX conferred a worse prognosis than pCA IX alone (P=0.05). A model was then developed where the study population was divided into three groups: group 1 had expression of EGFR without coexpression of MMP-9 or pCA IX (number=21); group 2 had no expression of EGFR (number=75); and group 3 had coexpression of EGFR with pCA IX or MMP-9 or both (number=70). Group 3 had a worse prognosis than either groups 1 or 2 (P=0.0003 and 0.027, respectively) and group 1 had a better prognosis than group 2 (P=0.036). These data identify two cohorts of EGFR-positive patients with diametrically opposite prognoses. The group expressing either EGFR and or both MMP-9 and pCA IX may identify a group of patients with activated EGFR, which is of clinical relevance with the advent of EGFR-targeted therapies. © 2004 Cancer Research UK.

Impact and interest:

43 citations in Scopus
41 citations in Web of Science®
Search Google Scholar™

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 65719
Item Type: Journal Article
Refereed: Yes
Additional URLs:
Keywords: CA IX, EGFR, MMP-9, NSCLC, carbonate dehydratase, carbonate dehydratase IX, epidermal growth factor receptor, gelatinase B, unclassified drug, CA9 protein, human, tumor antigen, tumor marker, adult, aged, article, cancer surgery, cancer survival, controlled study, female, gene activation, human, human tissue, lung non small cell cancer, major clinical study, male, priority journal, prognosis, protein expression, protein targeting, biosynthesis, gene expression profiling, gene expression regulation, genetics, immunohistochemistry, lung tumor, middle aged, pathology, retrospective study, theoretical model, Antigens, Neoplasm, Carbonic Anhydrases, Carcinoma, Non-Small-Cell Lung, Gene Expression Regulation, Neoplastic, Humans, Lung Neoplasms, Matrix Metalloproteinase 9, Models, Theoretical, Receptor, Epidermal Growth Factor, Retrospective Studies, Tumor Markers, Biological
DOI: 10.1038/sj.bjc.6602149
ISSN: 0007-0920
Divisions: Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
Copyright Owner: Copyright 2004 Nature Publishing Group
Deposited On: 07 Jan 2014 06:49
Last Modified: 09 Jan 2014 02:05

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page